VXRT - Vaxart, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
VXRT price evolution
VXRT
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.76 | $33.24 | $43.28 | $48.43 |
| Short term investments | $4.96 | $19.8 | $24.63 | $23.38 |
| Net receivables | $3.01 | $0.42 | $0.03 | $0.26 |
| Inventory | ||||
| Total current assets | $45.54 | $57.1 | $71.26 | $75.83 |
| Long term investments | ||||
| Property, plant & equipment | $36.57 | $38.68 | $40.72 | $42.22 |
| Goodwill & intangible assets | $8.8 | $8.98 | $9.16 | $9.35 |
| Total noncurrent assets | $46.29 | $48.54 | $51.39 | $54.02 |
| Total investments | $4.96 | $19.8 | $24.63 | $23.38 |
| Total assets | $91.83 | $105.64 | $122.65 | $129.85 |
| Current liabilities | ||||
| Accounts payable | $1.58 | $1.34 | $4.2 | $3.88 |
| Deferred revenue | $0.08 | $0.28 | $1.6 | |
| Short long term debt | $2.7 | $0 | $2.43 | $2.34 |
| Total current liabilities | $13.72 | $11.27 | $13.88 | $15.68 |
| Long term debt | $17.39 | $17.94 | $18.57 | $19.17 |
| Total noncurrent liabilities | $20.3 | $22.85 | $23.7 | $24.41 |
| Total debt | $20.09 | $17.94 | $21 | $21.52 |
| Total liabilities | $34.02 | $34.12 | $37.58 | $40.1 |
| Shareholders' equity | ||||
| Retained earnings | -$409.57 | -$392.2 | -$374.8 | -$352.25 |
| Other shareholder equity | -$0 | -$0.01 | -$0.02 | -$0.07 |
| Total shareholder equity | $57.8 | $71.52 | $85.07 | $89.75 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $34.76 | $15.18 | $143.75 | $126.87 |
| Short term investments | $4.96 | $49.7 | $22.74 | |
| Net receivables | $3.01 | $0.02 | $0.07 | $0.33 |
| Inventory | ||||
| Total current assets | $45.54 | $99.45 | $169.17 | $128.53 |
| Long term investments | $16.21 | |||
| Property, plant & equipment | $36.57 | $41.3 | $19.77 | $8.32 |
| Goodwill & intangible assets | $8.8 | $9.53 | $15.13 | $15.36 |
| Total noncurrent assets | $46.29 | $54.4 | $52 | $24.05 |
| Total investments | $4.96 | $49.7 | $38.95 | |
| Total assets | $91.83 | $153.85 | $221.17 | $152.58 |
| Current liabilities | ||||
| Accounts payable | $1.58 | $5.51 | $3.87 | $2.13 |
| Deferred revenue | $2 | |||
| Short long term debt | $2.7 | $2.23 | $1.01 | $2.05 |
| Total current liabilities | $13.72 | $17.92 | $10.78 | $11.76 |
| Long term debt | $17.39 | $19.48 | $12 | $5.16 |
| Total noncurrent liabilities | $20.3 | $25.33 | $22.85 | $17.41 |
| Total debt | $20.09 | $21.7 | $13.01 | $7.21 |
| Total liabilities | $34.02 | $43.25 | $33.64 | $29.18 |
| Shareholders' equity | ||||
| Retained earnings | -$409.57 | -$327.11 | -$219.35 | -$148.88 |
| Other shareholder equity | -$0 | -$0.3 | -$0.07 | |
| Total shareholder equity | $57.8 | $110.6 | $187.53 | $123.4 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.25 | $2.1 | $1.36 | $0.68 |
| Cost of revenue | ||||
| Gross Profit | $3.25 | $2.1 | $1.36 | $0.68 |
| Operating activities | ||||
| Research & development | $14.71 | $15 | $18.81 | $19.62 |
| Selling, general & administrative | $5.44 | $4.92 | $5.6 | $6.63 |
| Total operating expenses | $20.14 | $19.92 | $24.41 | $26.25 |
| Operating income | -$16.9 | -$17.82 | -$23.05 | -$25.57 |
| Income from continuing operations | ||||
| EBIT | -$17.2 | -$17.36 | -$22.53 | -$25.11 |
| Income tax expense | $0.17 | $0.04 | $0.02 | $0.03 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$17.38 | -$17.4 | -$22.55 | -$25.14 |
| Income (for common shares) | -$17.38 | -$17.4 | -$22.55 | -$25.14 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.38 | $0.11 | $0.89 | $4.05 |
| Cost of revenue | ||||
| Gross Profit | $7.38 | $0.11 | $0.89 | $4.05 |
| Operating activities | ||||
| Research & development | $68.14 | $81.05 | $48.75 | $19.86 |
| Selling, general & administrative | $22.58 | $29.39 | $21.89 | $15.2 |
| Total operating expenses | $90.73 | $114.69 | $73.64 | $34.22 |
| Operating income | -$83.35 | -$114.59 | -$72.75 | -$30.17 |
| Income from continuing operations | ||||
| EBIT | -$82.2 | -$107.69 | -$70.36 | -$31.98 |
| Income tax expense | $0.26 | $0.07 | $0.11 | $0.24 |
| Interest expense | $1.87 | |||
| Net income | ||||
| Net income | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| Income (for common shares) | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$17.38 | -$17.4 | -$22.55 | -$25.14 |
| Operating activities | ||||
| Depreciation | $2.33 | $2.06 | $2.17 | $2.06 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.71 | $3.84 | $3.93 | $2.65 |
| Total cash flows from operations | -$13.52 | -$15 | -$17.47 | -$24.46 |
| Investing activities | ||||
| Capital expenditures | $0.1 | -$0.16 | -$0.45 | -$1.24 |
| Investments | $15 | $5.13 | -$1.13 | $26.7 |
| Total cash flows from investing | $15.1 | $4.97 | -$1.58 | $25.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.26 | $13.92 | $1.43 | |
| Net borrowings | ||||
| Total cash flows from financing | -$0.07 | -$0.01 | $13.9 | $1.42 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $1.52 | -$10.04 | -$5.16 | $2.42 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$82.47 | -$107.76 | -$70.47 | -$32.22 |
| Operating activities | ||||
| Depreciation | $8.62 | $5.8 | $4.21 | $2.71 |
| Business acquisitions & disposals | -$4.83 | |||
| Stock-based compensation | $14.13 | $13.59 | $8.87 | $4.36 |
| Total cash flows from operations | -$70.45 | -$94.78 | -$59.83 | -$23.75 |
| Investing activities | ||||
| Capital expenditures | -$1.75 | -$9.6 | -$5.16 | -$1.22 |
| Investments | $45.7 | -$10.81 | -$39.11 | |
| Total cash flows from investing | $43.95 | -$20.41 | -$49.1 | -$1.22 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $15.61 | $17.46 | $125.8 | $137.66 |
| Net borrowings | ||||
| Total cash flows from financing | $15.24 | $17.46 | $125.8 | $138.31 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$11.26 | -$97.73 | $16.88 | $113.34 |
News
Fundamentals
| Market cap | $116.62M |
|---|---|
| Enterprise value | $101.96M |
| Shares outstanding | 153.45M |
| Revenue | $7.38M |
|---|---|
| EBITDA | -$73.58M |
| EBIT | -$82.20M |
| Net Income | -$82.47M |
| Revenue Q/Q | 14.65K% |
| Revenue Y/Y | 6.80K% |
| P/E ratio | -1.41 |
|---|---|
| EV/Sales | 13.82 |
| EV/EBITDA | -1.39 |
| EV/EBIT | -1.24 |
| P/S ratio | 15.80 |
| P/B ratio | 2.02 |
| Book/Share | 0.38 |
| Cash/Share | 0.23 |
| EPS | -$0.54 |
|---|---|
| ROA | -73.31% |
| ROE | -108.45% |
| Debt/Equity | 0.59 |
|---|---|
| Net debt/EBITDA | 0.01 |
| Current ratio | 3.32 |
| Quick ratio | 3.32 |